HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suppression of human hepatoma growth in vivo by a monoclonal antibody against a Mr 45,000 protein.

Abstract
The monoclonal antibody T2-2 was originally raised against the colorectal carcinoma cell line LS174T and was found to bind to several other human carcinomas, including hepatoma and ovarian cancer. The goal of this study was to investigate the antitumor activity of mAb T2-2 in human tumor models and further characterize the antigen. mAb T2-2 inhibited the growth of human hepatocellular cell line SMMC 7721 in vivo and in vitro. Western blot analysis revealed that this mAb recognizes an unique Mr 45,000 band from tissue extracts of human hepatocellular carcinoma (HCC), which localizes to the cell periphery. In vitro cell assays indicate that T2-2 decreases cell adhesion to laminin, implying the functional role of T2-2 antigen in cell-matrix interaction and cell migration.
AuthorsYun Lin, Jing Feng, Dongling Yang, Yi Shen, Xiyun Yan
JournalCancer investigation (Cancer Invest) Vol. 24 Issue 8 Pg. 734-9 (Dec 2006) ISSN: 0735-7907 [Print] England
PMID17162555 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Laminin
  • Neoplasm Proteins
  • T2-2 monoclonal antibody
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Blotting, Western
  • Carcinoma, Hepatocellular (chemistry, drug therapy, pathology)
  • Cell Adhesion (drug effects)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cell Proliferation (drug effects)
  • Humans
  • Laminin (metabolism)
  • Liver Neoplasms (chemistry, drug therapy, pathology)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Proteins (analysis, antagonists & inhibitors, immunology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: